nach oben

Discover Oncology

Erschienen in:

01.04.2016 | Review

Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer

verfasst von: Handoo Rhee, Ian Vela, Eric Chung

Erschienen in: Discover Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The human prostate gland is an endocrine organ where dysregulation of various hormonal factors may play a pivotal role in the pathogenesis of prostate cancer. There is emerging epidemiological data to support the role of components of metabolic syndrome, namely, obesity, hypercholesterolaemia, diabetes and hyperinsulinaemia on the development and/or the progression of prostate cancer. Although the exact mechanisms behind the relationship between metabolic syndrome and prostate cancer remain largely unknown, various in vitro and animal experiments of metabolic syndrome models have been shown to promote survival, mitogenesis, metastasis and treatment resistance pathways, through various adaptive responses such as intracellular steroidogenesis and lipogenesis. Also, in a large proportion of men with metabolic syndrome, alteration in levels of hormones such as testosterone, leptin and adiponectin has been shown to contribute towards the aggression of prostate cancer. Whilst the exact bio-pathophysiological mechanisms between metabolic syndrome and prostate cancer are yet to be fully elucidated, medications that target specific components of metabolic syndrome have further provided evidence for the inter-relationship between metabolic syndrome, its components and prostate cancer. Emerging in vitro and molecular data is likely to bring us closer to utilizing this knowledge to target particular cancer survival pathways and improving outcomes for men with prostate cancer.

Siegel R , Miller KD, Jemal A. et al (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29

WHO. Overweight/obesity 2008. 2014 31/10/2014]; Available from: http://gamapserver.who.int/gho/interactive_charts/ncd/risk_factors/overweight_obesity/atlas.html

Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–5

Janus ED, Laatikainen T, Dunbar JA et al (2007) Overweight, obesity and metabolic syndrome in rural southeastern Australia. Med J Aust 187(3):147–52

Tonkin A, Barter P, Best J et al (2005) National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management—2005. Heart Lung Circ 14(4):275–91

Mottillo S, Filion KB, Genest J et al (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56(14):1113–32

Zadra G, Photopoulos C, Loda M (2013) The fat side of prostate cancer. Biochim Biophys Acta 1831(10):1518–32

Renehan AG1, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–78

Bhaskaran K, Douglas I, Forbes H et al (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5 · 24 million UK adults. Lancet 384(9945):755–765

10.

Laukkanen JA, Laaksonen DE, Niskanen L et al (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13(10):1646–50

11.

Kane CJ, Bassett WW, Sadetsky N et al (2005) Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol 173(3):732–6

12.

Neuhouser ML, Till C, Kristal A et al (2010) Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) 3(3):279–89

13.

Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 4(4):486–501

14.

Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–47

15.

Bassett WW, Cooperberg MR, Sadestsky N et al (2005) Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 66(5):1060–5

16.

Wright JL, Plymate SR, Porter MP et al (2013) Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis 16(2):204–208

17.

Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA (2013) Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 16(1):62–6

18.

Efstathiou JA, Bae K, Shipley WU et al (2007) Obesity and mortality in men with locally advanced prostate cancer. Cancer 110(12):2691–2699

19.

Flanagan J, Gray PK, Hahn N et al (2011) Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 22(4):801–7

20.

Sharma J, Gray KP, Evan C et al (2014) Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate 74(3):225–34

21.

Haggstrom C, Stocks T, Nagel G et al (2014) Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology 25(6):823–8

22.

Robinson WR, Poole C, Godley PA (2008) Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control 19(8):793–803

23.

Rickles AS, Iannuzzi JC, Mironov O et al (2013) Visceral obesity and colorectal cancer: are we missing the boat with BMI? J Gastrointest Surg 17(1):133–43, discussion p 143

24.

Fukui M, Tanaka M, Kadono M et al (2008) Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 31(5):930–1

25.

Banez LL, Hamilton RJ, Partin AW et al (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298(19):2275–80

26.

Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC (2012) The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Adv Urol 2012:248607

27.

Freedland SJ, Platz EA, Presi JC Jr et al (2006) Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175(2):500–4, discussion 504

28.

Sanli T, Steinberg GR, Singh G, Tsakiridis T (2014) AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther 15(2):156–69

29.

Larsson O, Morita M, Topisirovic I et al (2012) Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A 109(23):8977–82

30.

Zhang P, Li H, Tan X, Chen L, Wang S (2013) Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 37(3):207–18

31.

Decensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3(11):1451–61

32.

Bansal D, Undela K, D'Cruz S, Schifano F (2012) Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE 7(10), e46691

33.

Whittemore AS, Kolonel LN, Wu AH et al (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87(9):652–61

34.

SEARCH Database Study Group, Jayachandran J, Aronson WJ, Terris MK et al (2008) Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int 102(8):964–8

35.

Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR (2007) Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 109(6):1192–202

36.

Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG (2006) Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care 29(11):2427–32

37.

Kocelak P, Chudek J, Olszanecka-Glinianowicz M (2012) Prevalence of metabolic syndrome and insulin resistance in overweight and obese women according to the different diagnostic criteria. Minerva Endocrinol 37(3):247–54

38.

Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30(6):586–623

39.

Mounier C, Posner BI (2006) Transcriptional regulation by insulin: from the receptor to the gene. Can J Physiol Pharmacol 84(7):713–24

40.

Heni M, Hennenlotter J, Scharpf M et al (2012) Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and −2 are differentially expressed in prostate cancer. PLoS ONE 7(12), e50953 [Electronic Resource]

41.

Cox ME, Gleave ME, Zakikhani M et al (2009) Insulin receptor expression by human prostate cancers. Prostate 69:33–40

42.

Lubik AA, Gunter JH, Hendy SC et al (2011) Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71(17):5754–64

43.

Lubik AA, Gunter JH, Hollier BG et al (2013) IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer 20(2):173–86

44.

Huang CY, Yu HS, Lai TY et al (2011) Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol 226(5):1274–82

45.

Collins CC, Volik SV, Lapuk AV et al (2012) Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther 11(3):775–83

46.

YuPeng L, LuXue Z, PengFei L et al (2015) Cholesterol levels in blood and the risk of prostate cancer: a meta-analysis of 14 prospective studies. Cancer Epidemiol Biomarkers Prev 24(7):1086–93

47.

Bhindi B, Locke J, Alibhai SM et al. (2014) Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol 67(10):64–70

48.

Harding J, Sooriyakumaran M, Anstey KJ et al. (2015) The metabolic syndrome and cancer: is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components? Diabetes Metab. doi:10.1016/j.diabet.2015.04.006

49.

Kang M, Jeong CW, Ku JH, Kwak C, Kim HH (2015) Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy. PLoS ONE 10(3), e0122438

50.

Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L (2010) Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 6(2):71–82

51.

Herroon MK, Rajagurubandara E, Hardaway AL et al (2013) Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 4(11):2108–23

52.

Venkatasubramanian PN, Brendler CB, Plunkett BA et al (2014) Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study. Prostate 74(3):326–35

53.

Finley DS, Calvert VS, Inokuchi J et al (2009) Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 182(4):1621–7

54.

van Roermund JG, Hinnen KA, Tolman CJ et al (2011) Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients. BJU Int 107(11):1775–9

55.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–38

56.

Marignol L, rivera-Figueroa K, Lynch T, Hollywood D (2013) Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol 10(7):405–13

57.

Ranasinghe WK, Sengupta S, Williams S et al (2014) The effects of nonspecific HIF1alpha inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med 3(2):245–51

58.

Fuster JJ, Zuriaga MA, Ngo DT et al. (2014) Non-canonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes,

59.

Rojas A, Liu G, Coleman I et al (2011) IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 30(20):2345–55

60.

Pernicova I, Korbonits M (2014) Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10(3):143–56

61.

Shi M, Zhou X, Zhang Z et al (2014) A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3. Toxicology Letters 228(3):133–9

62.

Demir U, Koehler A, Scnieder R, Schweiger S, Klocker H (2014) Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer 14:52

63.

Saenz A, Fernandez-Esteban I, Mataix A et al. (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev, (3): p. CD002966

64.

Libby G, Donnelly LA, Donnan PT et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9):1620–5

65.

Spratt DE, Zhang C, Zumsteg ZS et al (2013) Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63(4):709–16

66.

Nobes JP, Langley SE, Klopper R, Russell-Jones D, Laing RW (2012) A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 109(10):1495–502

67.

Rothermundt C, Hayoz S, Templeton AJ et al. (2014) Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). Eur Urol 66(3):468–74

68.

Segawa Y, Yoshimura R, Hase T et al (2002) Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51(2):108–16

69.

Colmers IN, Bowker SL, Johnson JA (2012) Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 38(6):475–84

70.

Park YH, Seo SY, Lee E et al (2013) Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-B pathway. J Urol 189(4):1547–52

71.

Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ (2010) Is statin use associated with prostate cancer aggressiveness? BJU Int 105(9):1222–5

72.

Nordstrom T, Clements M, Karlsson R, Adolfsson J, Gronberg H (2015) The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 51(6):725–33

73.

Ghalali A, Wiklund F, Zheng H, Stenius U, Hogberg J (2014) Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis 35(7):1547–55

74.

Babcook MA , Sramkoski RM, Fujioka H et al. (2014) Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Cell Death Dis e1536

75.

Chi KN, Gleave ME, Fazli L et al (2012) A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 18(12):3407–13

76.

Bassett JK, Severi G, Baglietto L et al (2012) Weight change and prostate cancer incidence and mortality. Int J Cancer 131(7):1711–9

77.

Schmitz KH, Courneya KS, Matthews C et al (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7):1409–26

78.

Hayes SC, Spence RR, Galvao DA, Newton RU (2009) Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 12(4):428–34

79.

Cheung AS, Pattison D, Bretherton I et al (2013) Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Androl 1(4):583–9

80.

Rhee H, Gunter JH, Heathcote P et al. (2014) Adverse effects of androgen deprivation therapy in prostate cancer and their management. BJU Int 15(Suppl5):3–13

81.

Cormie P, Galvao GA, Spry N et al. (2014) Can Supervised exercise prevent treatment toxicity in prostate cancer patients initiating androgen deprivation therapy: a randomised controlled trial. BJU Int

82.

Gardner JR, Livingston PM, Fraser SF (2014) Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32(4):335–46

83.

Masko EM, Allott EH, Freedland SJ (2013) The relationship between nutrition and prostate cancer: is more always better? Eur Urol 63(5):810–820

84.

Alliance, N.-N.V.D.P. Guidelines for the Management of Absolute Cardiovascular Disease Risk. 2012 [cited 2014 06/05]; Available from: http://strokefoundation.com.au/site/media/AbsoluteCVD_GL_webready.pdf

85.

Esposito K, Chiodini P, Capuano A et al (2013) Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Investig 36(2):132–9

86.

Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6):535–541

87.

Coleman CI, Baker WL, Kluger J, White CM (2008) Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 26(4):622–629

Titel: Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer
verfasst von: Handoo Rhee
Ian Vela
Eric Chung
Publikationsdatum: 01.04.2016
Verlag: Springer US
Erschienen in: Discover Oncology / Ausgabe 2/2016
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-015-0238-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer

Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk

Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression

Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie